Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Change in Acquisitions & Divestments: 2017-2024

Historic Change in Acquisitions & Divestments for UroGen Pharma (URGN) over the last 8 years, with Dec 2024 value amounting to $107.7 million.

  • UroGen Pharma's Change in Acquisitions & Divestments rose 231.19% to $40.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $180.9 million, marking a year-over-year increase of 338.37%. This contributed to the annual value of $107.7 million for FY2024, which is 119.48% up from last year.
  • Latest data reveals that UroGen Pharma reported Change in Acquisitions & Divestments of $107.7 million as of FY2024, which was up 119.48% from $49.1 million recorded in FY2023.
  • In the past 5 years, UroGen Pharma's Change in Acquisitions & Divestments registered a high of $124.1 million during FY2020, and its lowest value of $49.1 million during FY2023.
  • For the 3-year period, UroGen Pharma's Change in Acquisitions & Divestments averaged around $73.7 million, with its median value being $64.3 million (2022).
  • As far as peak fluctuations go, UroGen Pharma's Change in Acquisitions & Divestments soared by 136.05% in 2020, and later tumbled by 56.29% in 2021.
  • UroGen Pharma's Change in Acquisitions & Divestments (Yearly) stood at $124.1 million in 2020, then crashed by 56.29% to $54.3 million in 2021, then grew by 18.55% to $64.3 million in 2022, then dropped by 23.71% to $49.1 million in 2023, then spiked by 119.48% to $107.7 million in 2024.